Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategies
Authors:
- 19 September 2024
- journal article
- review article
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 103, 101302
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Adverse events of antibody–drug conjugates on the ocular surface in cancer therapyClinical and Translational Oncology, 2023
- Vision-related quality of life amongst patients with low vision and blindness in a resource-limited countryInternational Ophthalmology, 2022
- Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experienceAmerican Journal of Hematology, 2022
- Chemotherapy-Induced Hyperopic Surprise in a Woman With Multiple MyelomaJAMA Ophthalmology, 2022
- Corneal features in trastuzumab emtansine treatment: not a rare occurrenceBreast Cancer Research and Treatment, 2019
- A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancerCancer, 2012
- Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eyeCellular and Molecular Life Sciences, 2010
- Development of the 25-list-item National Eye Institute Visual Function QuestionnaireArchives of Ophthalmology (1950), 2001
- Reliability and Validity of the Ocular Surface Disease IndexArchives of Ophthalmology (1950), 2000
- Mechanism of action of DNA topoisomerase inhibitorsStem Cells, 1995